Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

This observational study looks at how well a combination of oral chemotherapy, radiation therapy, and a PD-1 inhibitor (an immunotherapy drug) works in patients with advanced non-small cell lung cancer (NSCLC) who have a poor performance status (PS score 2), meaning they have significant limitations in daily activities, and whose tumors do not have the typical gene mutations that respond to targeted therapies. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with advanced non-small cell lung cancer (stage IIIB or IV, or recurring/progressing disease) - Your tumor does NOT have EGFR, ALK, or ROS1 gene mutations - You have significant physical limitations due to your illness (performance status score of 2) - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have received prior systemic chemotherapy for advanced disease (with some exceptions for early-stage prior treatment) - You have uncontrolled brain metastases - You have serious heart, liver, or autoimmune conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.